MA52920A - Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f - Google Patents

Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Info

Publication number: MA52920A
Authority: MA; Morocco
Prior art keywords: pyridinoylpiperidine; compositions; methods relating; ht1f agonists; ht1f
Prior art date: 2016-12-06

Application number

MA052920A

Other languages

English (en)

Other versions

MA52920B1 (fr

Inventor

Brigida Allieri

Paul Fagan

Emma Sharp

Raymond D Skwierczynski

Original Assignee

Colucid Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-06

Filing date

2017-12-05

Publication date

2021-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52920(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-05 Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc

2021-04-28 Publication of MA52920A publication Critical patent/MA52920A/fr

2021-11-30 Publication of MA52920B1 publication Critical patent/MA52920B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA52920A 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f MA52920B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662430662P	2016-12-06	2016-12-06
PCT/US2017/064652 WO2018106657A1 (fr)	2016-12-06	2017-12-05	Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Publications (2)

Publication Number	Publication Date
MA52920A true MA52920A (fr)	2021-04-28
MA52920B1 MA52920B1 (fr)	2021-11-30

Family

ID=60972336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA52920A MA52920B1 (fr)	2016-12-06	2017-12-05	Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Country Status (38)

Country	Link
US (1)	US11053214B2 (fr)
EP (1)	EP3551617B1 (fr)
JP (4)	JP2020500936A (fr)
KR (3)	KR20210102497A (fr)
CN (3)	CN115385893A (fr)
AU (1)	AU2017373784B2 (fr)
BR (1)	BR112019010934A2 (fr)
CA (1)	CA3043772C (fr)
CL (1)	CL2019001426A1 (fr)
CO (1)	CO2019005290A2 (fr)
CR (1)	CR20190251A (fr)
CY (1)	CY1124540T1 (fr)
DK (1)	DK3551617T3 (fr)
DO (1)	DOP2019000139A (fr)
EA (1)	EA201991112A1 (fr)
EC (1)	ECSP19040190A (fr)
ES (1)	ES2889476T3 (fr)
HR (1)	HRP20211557T1 (fr)
HU (1)	HUE056820T2 (fr)
IL (1)	IL266598B2 (fr)
JO (1)	JOP20190129B1 (fr)
LT (1)	LT3551617T (fr)
MA (1)	MA52920B1 (fr)
MD (1)	MD3551617T2 (fr)
MX (2)	MX2019006520A (fr)
MY (1)	MY196855A (fr)
NZ (1)	NZ752906A (fr)
PE (2)	PE20241297A1 (fr)
PH (1)	PH12019501252B1 (fr)
PL (1)	PL3551617T3 (fr)
PT (1)	PT3551617T (fr)
RS (1)	RS62415B1 (fr)
SI (1)	SI3551617T1 (fr)
TN (1)	TN2019000174A1 (fr)
TW (1)	TWI671290B (fr)
UA (1)	UA124433C2 (fr)
WO (1)	WO2018106657A1 (fr)
ZA (1)	ZA201903449B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI826514B (zh)	2018-09-04	2023-12-21	美商美國禮來大藥廠	用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh)	2019-07-09	2022-09-01	美商美國禮來大藥廠	大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) *	2019-11-22	2021-06-08	广东东阳光药业有限公司	吡啶酰基哌啶衍生物及其用途
BR112023022680A2 (pt)	2021-05-07	2024-01-23	Lilly Co Eli	Composições com sabor mascarado de hemissuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-benzamida, comprimido desintegrante oralmente compreendendo o mesmo, seus usos, e processo para fabricação de comprimido
CN116270505A (zh) *	2021-12-20	2023-06-23	南京科默生物医药有限公司	含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
TWI263497B (en)	2002-03-29	2006-10-11	Lilly Co Eli	Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en)	2005-01-24	2006-08-10	Pozen Inc.	Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US20100256187A1 (en)	2009-04-02	2010-10-07	Colucid Pharmaceuticals, Inc.	Composition of 2,4,6- trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en)	2010-04-02	2014-04-15	Colucid Pharmaceuticals, Inc.	Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
WO2012163365A1 (fr)	2011-06-01	2012-12-06	Concit Pharma Aps	Combinaisons d'agonistes de récepteur de sérotonine pour le traitement de troubles du mouvement
WO2018010345A1 (fr)	2016-07-15	2018-01-18	杭州领业医药科技有限公司	Forme cristalline d'un agoniste de récepteur, procédé de fabrication et composition pharmaceutique associés
TWI754772B (zh)	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

2017
- 2017-12-05 US US16/467,208 patent/US11053214B2/en active Active
- 2017-12-05 PT PT17829372T patent/PT3551617T/pt unknown
- 2017-12-05 JO JOP/2019/0129A patent/JOP20190129B1/ar active
- 2017-12-05 CR CR20190251A patent/CR20190251A/es unknown
- 2017-12-05 IL IL266598A patent/IL266598B2/en unknown
- 2017-12-05 KR KR1020217025499A patent/KR20210102497A/ko not_active Ceased
- 2017-12-05 MY MYPI2019003189A patent/MY196855A/en unknown
- 2017-12-05 MX MX2019006520A patent/MX2019006520A/es unknown
- 2017-12-05 PE PE2023002466A patent/PE20241297A1/es unknown
- 2017-12-05 SI SI201730881T patent/SI3551617T1/sl unknown
- 2017-12-05 NZ NZ752906A patent/NZ752906A/en unknown
- 2017-12-05 PL PL17829372T patent/PL3551617T3/pl unknown
- 2017-12-05 AU AU2017373784A patent/AU2017373784B2/en active Active
- 2017-12-05 WO PCT/US2017/064652 patent/WO2018106657A1/fr active Application Filing
- 2017-12-05 BR BR112019010934A patent/BR112019010934A2/pt not_active Application Discontinuation
- 2017-12-05 UA UAA201905483A patent/UA124433C2/uk unknown
- 2017-12-05 MA MA52920A patent/MA52920B1/fr unknown
- 2017-12-05 JP JP2019551251A patent/JP2020500936A/ja active Pending
- 2017-12-05 MD MDE20191169T patent/MD3551617T2/ro unknown
- 2017-12-05 CA CA3043772A patent/CA3043772C/fr active Active
- 2017-12-05 CN CN202210944298.6A patent/CN115385893A/zh active Pending
- 2017-12-05 RS RS20211233A patent/RS62415B1/sr unknown
- 2017-12-05 PE PE2019001167A patent/PE20191134A1/es unknown
- 2017-12-05 PH PH1/2019/501252A patent/PH12019501252B1/en unknown
- 2017-12-05 ES ES17829372T patent/ES2889476T3/es active Active
- 2017-12-05 LT LTEPPCT/US2017/064652T patent/LT3551617T/lt unknown
- 2017-12-05 DK DK17829372.6T patent/DK3551617T3/da active
- 2017-12-05 EA EA201991112A patent/EA201991112A1/ru unknown
- 2017-12-05 KR KR1020227046438A patent/KR20230008257A/ko not_active Ceased
- 2017-12-05 CN CN202210944373.9A patent/CN115385894A/zh active Pending
- 2017-12-05 TW TW106142535A patent/TWI671290B/zh active
- 2017-12-05 MX MX2021014139A patent/MX2021014139A/es unknown
- 2017-12-05 EP EP17829372.6A patent/EP3551617B1/fr active Active
- 2017-12-05 CN CN201780075750.7A patent/CN110291079A/zh active Pending
- 2017-12-05 TN TNP/2019/000174A patent/TN2019000174A1/en unknown
- 2017-12-05 HU HUE17829372A patent/HUE056820T2/hu unknown
- 2017-12-05 KR KR1020197016255A patent/KR20190075130A/ko active Application Filing
- 2017-12-05 HR HRP20211557TT patent/HRP20211557T1/hr unknown
2019
- 2019-05-23 CO CONC2019/0005290A patent/CO2019005290A2/es unknown
- 2019-05-27 CL CL2019001426A patent/CL2019001426A1/es unknown
- 2019-05-30 ZA ZA2019/03449A patent/ZA201903449B/en unknown
- 2019-05-30 DO DO2019000139A patent/DOP2019000139A/es unknown
- 2019-06-06 EC ECSENADI201940190A patent/ECSP19040190A/es unknown
2021
- 2021-09-22 JP JP2021153729A patent/JP2022000451A/ja active Pending
- 2021-10-05 CY CY20211100864T patent/CY1124540T1/el unknown
2023
- 2023-06-26 JP JP2023104019A patent/JP7561240B2/ja active Active
2024
- 2024-09-20 JP JP2024163884A patent/JP2024178323A/ja active Pending

Also Published As

Publication number	Publication date
RS62415B1 (sr)	2021-10-29
NZ752906A (en)	2021-07-30
PL3551617T3 (pl)	2021-12-20
MA52920B1 (fr)	2021-11-30
JP2020500936A (ja)	2020-01-16
PH12019501252B1 (en)	2024-05-24
MX2021014139A (es)	2022-05-24
EP3551617A1 (fr)	2019-10-16
CA3043772A1 (fr)	2018-06-14
MD3551617T2 (ro)	2021-12-31
IL266598B1 (en)	2024-01-01
PE20241297A1 (es)	2024-06-24
JP7561240B2 (ja)	2024-10-03
KR20210102497A (ko)	2021-08-19
CA3043772C (fr)	2022-06-07
PT3551617T (pt)	2021-10-04
PE20191134A1 (es)	2019-09-02
LT3551617T (lt)	2021-10-11
SI3551617T1 (sl)	2021-11-30
MY196855A (en)	2023-05-05
BR112019010934A2 (pt)	2019-10-01
PH12019501252A1 (en)	2019-12-02
US20200087279A1 (en)	2020-03-19
IL266598A (en)	2019-07-31
CL2019001426A1 (es)	2019-10-11
ECSP19040190A (es)	2019-08-30
JP2024178323A (ja)	2024-12-24
MX2019006520A (es)	2019-08-21
US11053214B2 (en)	2021-07-06
TN2019000174A1 (en)	2020-10-05
CN115385893A (zh)	2022-11-25
HUE056820T2 (hu)	2022-03-28
AU2017373784A1 (en)	2019-05-16
JP2023123678A (ja)	2023-09-05
CN110291079A (zh)	2019-09-27
EA201991112A1 (ru)	2019-10-31
EP3551617B1 (fr)	2021-08-11
CY1124540T1 (el)	2022-07-22
DOP2019000139A (es)	2019-08-15
KR20230008257A (ko)	2023-01-13
ZA201903449B (en)	2021-02-24
JOP20190129B1 (ar)	2023-03-28
CN115385894A (zh)	2022-11-25
CR20190251A (es)	2019-08-26
JP2022000451A (ja)	2022-01-04
TW201833097A (zh)	2018-09-16
UA124433C2 (uk)	2021-09-15
HRP20211557T1 (hr)	2022-01-07
AU2017373784B2 (en)	2020-04-23
KR20190075130A (ko)	2019-06-28
DK3551617T3 (da)	2021-09-13
IL266598B2 (en)	2024-05-01
JOP20190129A1 (ar)	2019-05-29
WO2018106657A1 (fr)	2018-06-14
CO2019005290A2 (es)	2019-05-31
ES2889476T3 (es)	2022-01-12
TWI671290B (zh)	2019-09-11

Publication	Publication Date	Title
MA43380A (fr)	2018-10-10	Récepteurs chimériques modifiés et compositions et procédés associés
HK1257295A1 (zh)	2019-10-18	用於免疫腫瘤學的組合物和方法
EP3380602A4 (fr)	2019-09-25	Procédés et compositions se rapportant à des récepteurs antigéniques chimériques
EP3397261A4 (fr)	2019-07-03	Procédés et compositions se rapportant aux chondrisomes
EP3471745A4 (fr)	2020-01-22	Procédés et compositions pour réduire le stress oxydatif
EP3373906A4 (fr)	2019-09-25	Compositions et procédés destinés à une application sur la peau
MA45779A (fr)	2019-06-05	Polypeptides immunomdulateurs et compositions et procédés associés
EP3352774A4 (fr)	2019-04-03	Compositions de flavonoïdes et procédés d'utilisation
MA46427A (fr)	2018-08-15	Compositions d'oligonucléotides et procédés associés
EP3389672A4 (fr)	2019-08-14	Compositions et procédés de traitement de maladies hépatiques
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
EP3316909A4 (fr)	2019-01-09	Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP4083203C0 (fr)	2024-08-07	Compositions et procédés destinés à réduire la néovascularisation oculaire
EP2971142A4 (fr)	2016-10-19	Compositions et procédés destinés à moduler l'expression de tau
PL3274469T3 (pl)	2020-10-05	Kompozycje i sposoby wykrywania zanieczyszczenia biologicznego
EP3289064A4 (fr)	2019-01-23	Compositions et procédés pour la détection d'allergènes
MA52920A (fr)	2021-04-28	Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f
DK3494119T3 (da)	2024-12-02	Forbindelser og sammensætninger og anvendelser deraf
PT3261437T (pt)	2019-11-29	Compostos e composições fungicidas
EP3503733C0 (fr)	2024-03-20	Composés et compositions insectifuges et procédés associés
EP3355881A4 (fr)	2019-05-08	Compositions orales de taxane et procédés associés
EP3298151A4 (fr)	2019-04-10	Procédés et compositions pour déterminer le ph
EP3412344A4 (fr)	2019-08-21	Composition d'agent extincteur
MA42527A (fr)	2021-04-07	Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
EP3349788A4 (fr)	2019-06-05	Compositions antimalariques et procédés